-

$undefined

N/A

(N/A)

Oragenics, Inc. NYSE American:OGEN Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.

Location: 1990 Main Street, Sarasota, FL, 34236, United States | Website: https://www.oragenics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.977M

Cash

3.421M

Avg Qtr Burn

-1.911M

Short % of Float

4.25%

Insider Ownership

13.28%

Institutional Own.

1.31%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.